Jurgis Alvikas1, Sara P Myers, Charles B Wessel, David O Okonkwo, Bellal Joseph, Carlos Pelaez, Cody Doberstein, Andrew R Guillotte, Matthew R Rosengart, Matthew D Neal. 1. From the Department of Surgery (J.A., S.P.M., M.R.R., M.D.N.), University of Pittsburgh Medical Center; University of Pittsburgh Health Sciences Library System (C.B.W.); Department of Neurological Surgery (D.O.O.), University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; Department of Surgery (B.J.), University of Arizona, Tucson, Arizona; The Iowa Clinic (C.P.), Des Moines, Iowa; Warren Alpert Medical School of Brown University (C.D.), Providence, Rhode Island; Division of Neurological Surgery (A.R.G.), University of Missouri School of Medicine, Columbia, Missouri; and Department of Critical Care Medicine (M.R.R., M.D.N.), University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND: Platelet transfusion has been utilized to reverse platelet dysfunction in patients on preinjury antiplatelets who have sustained a traumatic intracranial hemorrhage (tICH); however, there is little evidence to substantiate this practice. The objective of this study was to perform a systematic review on the impact of platelet transfusion on survival, hemorrhage progression and need for neurosurgical intervention in patients with tICH on prehospital antiplatelet medication. METHODS: Controlled, observational and randomized, prospective and retrospective studies describing tICH, preinjury antiplatelet use, and platelet transfusion reported in PubMed, Embase, Cochrane Reviews, Cochrane Trials and Cochrane DARE databases between January 1987 and March 2019 were included. Investigations of concomitant anticoagulant use were excluded. Risk of bias was assessed using the Newcastle-Ottawa scale. We calculated pooled estimates of relative effect of platelet transfusion on the risk of death, hemorrhage progression and need for neurosurgical intervention using the methods of Dersimonian-Laird random-effects meta-analysis. Sensitivity analysis established whether study size contributed to heterogeneity. Subgroup analyses determined whether antiplatelet type, additional blood products/reversal agents, or platelet function assays impacted effect size using meta-regression. RESULTS: Twelve of 18,609 screened references were applicable to our questions and were qualitatively and quantitatively analyzed. We found no association between platelet transfusion and the risk of death in patients with tICH taking prehospital antiplatelets (odds ratio [OR], 1.29; 95% confidence interval [CI], 0.76-2.18; p = 0.346; I = 32.5%). There was no significant reduction in hemorrhage progression (OR, 0.88; 95% CI, 0.34-2.28; p = 0.788; I = 78.1%). There was no significant reduction in the need for neurosurgical intervention (OR, 1.00; 95% CI, 0.53-1.90, p = 0.996; I = 59.1%; p = 0.032). CONCLUSION: Current evidence does not support the use of platelet transfusion in patients with tICH on prehospital antiplatelets, highlighting the need for a prospective evaluation of this practice. LEVEL OF EVIDENCE: Systematic Reviews and Meta-Analyses, Level III.
BACKGROUND: Platelet transfusion has been utilized to reverse platelet dysfunction in patients on preinjury antiplatelets who have sustained a traumatic intracranial hemorrhage (tICH); however, there is little evidence to substantiate this practice. The objective of this study was to perform a systematic review on the impact of platelet transfusion on survival, hemorrhage progression and need for neurosurgical intervention in patients with tICH on prehospital antiplatelet medication. METHODS: Controlled, observational and randomized, prospective and retrospective studies describing tICH, preinjury antiplatelet use, and platelet transfusion reported in PubMed, Embase, Cochrane Reviews, Cochrane Trials and Cochrane DARE databases between January 1987 and March 2019 were included. Investigations of concomitant anticoagulant use were excluded. Risk of bias was assessed using the Newcastle-Ottawa scale. We calculated pooled estimates of relative effect of platelet transfusion on the risk of death, hemorrhage progression and need for neurosurgical intervention using the methods of Dersimonian-Laird random-effects meta-analysis. Sensitivity analysis established whether study size contributed to heterogeneity. Subgroup analyses determined whether antiplatelet type, additional blood products/reversal agents, or platelet function assays impacted effect size using meta-regression. RESULTS: Twelve of 18,609 screened references were applicable to our questions and were qualitatively and quantitatively analyzed. We found no association between platelet transfusion and the risk of death in patients with tICH taking prehospital antiplatelets (odds ratio [OR], 1.29; 95% confidence interval [CI], 0.76-2.18; p = 0.346; I = 32.5%). There was no significant reduction in hemorrhage progression (OR, 0.88; 95% CI, 0.34-2.28; p = 0.788; I = 78.1%). There was no significant reduction in the need for neurosurgical intervention (OR, 1.00; 95% CI, 0.53-1.90, p = 0.996; I = 59.1%; p = 0.032). CONCLUSION: Current evidence does not support the use of platelet transfusion in patients with tICH on prehospital antiplatelets, highlighting the need for a prospective evaluation of this practice. LEVEL OF EVIDENCE: Systematic Reviews and Meta-Analyses, Level III.
Authors: Sara P Myers; Katherine M Reitz; Charles B Wessel; Matthew D Neal; Jennifer A Corbelli; Leslie R M Hausmann; Matthew R Rosengart Journal: J Surg Res Date: 2018-12-03 Impact factor: 2.192
Authors: Dennis Yong Kim; Michael O'Leary; Andrew Nguyen; Amy Kaji; Scott Bricker; Angela Neville; Fred Bongard; Brant Putnam; David Plurad Journal: J Neurotrauma Date: 2015-09-08 Impact factor: 5.269
Authors: Seif Tarek El-Swaify; Mazen A Refaat; Sara H Ali; Abdelrahman E Mostafa Abdelrazek; Pavly Wagih Beshay; Menna Kamel; Bassem Bahaa; Abdelrahman Amir; Ahmed Kamel Basha Journal: Trauma Surg Acute Care Open Date: 2022-01-05
Authors: Jurgis Alvikas; Mazen Zenati; Insiyah Campwala; Jan O Jansen; Adnan Hassoune; Heather Phelos; David O Okonkwo; Matthew D Neal Journal: J Trauma Acute Care Surg Date: 2022-01-01 Impact factor: 3.697
Authors: Benjamin E Zusman; C Edward Dixon; Ruchira M Jha; Vincent A Vagni; Jeremy J Henchir; Shaun W Carlson; Keri L Janesko-Feldman; Zachary S Bailey; Deborah A Shear; Janice S Gilsdorf; Patrick M Kochanek Journal: J Neurotrauma Date: 2021-09-15 Impact factor: 4.869